Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Recruiting now

Conditions studied: Solid Tumor, Unspecified, Adult, Haematological Malignancy

In brief

Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region. Treatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.

Key facts

Study ID

NCT05695638

Run by

Morten Ladekarl

People needed

3000

Starts

2020-07-01

Expected to finish

2035-05-31

Last updated by the study team

2024-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Incurable, progressing and/or life-threatening cancer
• Expected residual survival of at least 3 months
• No efficient remaining standard treatment options
• Patient recruited from the Region of Northern Jutland, Denmark

You may not qualify if…

• WHO Performance Status >2
• Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment

Where it is running

• Department of Oncology, Aalborg University Hospital — Aalborg, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.